The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

Who Took Part

The study group was 60 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

In a randomized clinical trial, 60 patients with mixed hemorrhoids undergoing Milligan-Morgan surgery were divided into 2 groups: a study group (n = 30) and a control group (n = 30).

Upon surgical completion, patients in the study group received an intraoperative MBI to the surgical incisions.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

All patients, in both groups, then received the same standard postoperative on-demand intravenous lornoxicam protocol.

The primary outcome was anal pain intensity assessed by the visual analog scale scores at 6, 24, 48, and 72 hours.

Secondary outcomes included limb movement score, incision edema, duration of the first postoperative defecation, supplemental analgesic consumption, length of hospital stay, hospitalization costs, and serum levels of substance P, 5-hydroxytryptamine, and prostaglandin E2.

What Was Measured

The subject headings attached to it are Postoperative Pain, Methylene Blue, Hemorrhoidectomy, Pain Measurement, Piroxicam, Hemorrhoids and Length of Stay.

Author keywords: mixed hemorrhoids, pain management and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 60 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Medicine), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.